Clinical characteristics of patients according to protocol for treatment of acute myeloid leukemia (AML)
| Characteristic . | AML-10 protocol (n = 34) . | AML-13 protocol (n = 22) . | All patients (n = 56) . |
|---|---|---|---|
| Median (range) age, y | 47 (18-61) | 68 (61-78) | 54 (18-78) |
| Sex (M/F) | 17/17 | 8/14 | 25/31 |
| WBC, × 109/L | |||
| < 50 | 22 | 19 | 41 |
| 50-100 | 8 | 2 | 10 |
| > 100 | 4 | 1 | 5 |
| FAB class | |||
| M0 | 3 | 1 | 4 |
| M1 | 7 | 7 | 14 |
| M2 | 10 | 10 | 20 |
| M4 | 3 | — | 3 |
| M5 | 10 | 4 | 14 |
| M6 | 1 | — | 1 |
| Cytogenetic findings* | |||
| Favorable | 8 | 2 | 10 |
| Intermediate | 13 | 12 | 25 |
| Unfavorable | 10 | 4 | 14 |
| Induction | 34 | 22 | 56 |
| Consolidation | 33 | 18 | 51 |
| Consolidation II | — | 11 | 11 |
| ASCT | 28 | — | 28 |
| Characteristic . | AML-10 protocol (n = 34) . | AML-13 protocol (n = 22) . | All patients (n = 56) . |
|---|---|---|---|
| Median (range) age, y | 47 (18-61) | 68 (61-78) | 54 (18-78) |
| Sex (M/F) | 17/17 | 8/14 | 25/31 |
| WBC, × 109/L | |||
| < 50 | 22 | 19 | 41 |
| 50-100 | 8 | 2 | 10 |
| > 100 | 4 | 1 | 5 |
| FAB class | |||
| M0 | 3 | 1 | 4 |
| M1 | 7 | 7 | 14 |
| M2 | 10 | 10 | 20 |
| M4 | 3 | — | 3 |
| M5 | 10 | 4 | 14 |
| M6 | 1 | — | 1 |
| Cytogenetic findings* | |||
| Favorable | 8 | 2 | 10 |
| Intermediate | 13 | 12 | 25 |
| Unfavorable | 10 | 4 | 14 |
| Induction | 34 | 22 | 56 |
| Consolidation | 33 | 18 | 51 |
| Consolidation II | — | 11 | 11 |
| ASCT | 28 | — | 28 |
WBC indicates white blood cell count; FAB, French-American-British leukemia classification system; and ASCT, autologous stem-cell transplantation.
Available for 49 of 56 patients.